Study wrapper · #256
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.
Editor's note
A small retrospective chart review, useful but low in the evidence hierarchy. From 105 testosterone-treated men seeking lean mass and fat loss who were prescribed a thrice-daily combination of GHRP-6, GHRP-2, and sermorelin, only 14 met strict compliance criteria and were analysed. In those men, mean IGF-1 rose significantly from ~160 to ~239 ng/mL over an average of ~134 days, and the abstract notes that blocking estrogen (via aromatase inhibitor or tamoxifen) blunted the IGF-1 increase. The signal is consistent with the known pharmacology — GH secretagogues raise IGF-1 — but the design is weak: retrospective, uncontrolled, no placebo, tiny final sample, heavy selection for compliers, concurrent testosterone therapy, and a combination of three agents that cannot be individually attributed. IGF-1 is a surrogate marker, not a clinical outcome; the study measured no change in body composition, strength, or wasting. It suggests the combination raises IGF-1 with strict adherence and hints at an estrogen interaction, but supports no efficacy claim for sermorelin or GHRP-6 individually, and the men were not a deficiency population.
Plain-language abstract
This study reviewed medical records to see whether a combination of growth-hormone-stimulating peptides raised IGF-1, a blood marker that reflects growth-hormone activity. Because misuse of injected growth hormone is a concern, safer ways to raise the body's own growth hormone are of interest. The records came from 105 men already on testosterone therapy who wanted more lean muscle and less fat and were prescribed 100 micrograms each of GHRP-6, GHRP-2, and sermorelin three times a day. After checking who actually followed the regimen, only 14 men met the strict criteria for analysis. Their average age was about 33, and they were treated for an average of roughly 134 days. Their average IGF-1 rose significantly, from about 160 to about 239 nanograms per millilitre. Seven of the 14 men were also taking a drug that lowers estrogen (an aromatase inhibitor and/or tamoxifen), and in them the IGF-1 increase was smaller. The authors suggest the combination, taken faithfully three times daily, raises IGF-1 and might help men with wasting conditions. The study was small, looked back at records rather than testing prospectively, had no comparison group, used three drugs together plus testosterone, and measured only a blood marker — not muscle, fat, or any health outcome.